The UK’s First Oral GLP-1 Weight-Loss Treatment: Wegovy Pill Approved by MHRA
The MHRA approved the Wegovy pill on 11 June 2026 - a landmark in UK obesity treatment. Independent analysis of the clinical evidence, who qualifies, how costs compare, and what comes next for NHS access.
The UK has approved its first oral weight-loss GLP-1. What you need to know.
On 11 June 2026, the Medicines and Healthcare products Regulatory Agency approved the Wegovy pill, a once-daily oral semaglutide tablet for weight management in adults. This is the first GLP-1 tablet approved for weight loss in the UK and the first in Europe.
For people who have been researching treatment options but have not wanted an injection treatment, this is a meaningful change in the UK market. This article sets out what was approved, what the evidence shows, how the pill compares with current treatment routes, and what the near-term access picture looks like.
WeightLossComparison does not prescribe or supply treatment. This is editorial analysis.
What was approved
The licence covers Wegovy pill as an adjunct to a reduced-calorie diet and increased physical activity in:
- Adults with obesity, BMI 30 or above.
- Adults with overweight, BMI 27 to 29.9, with at least one weight-related comorbidity.
The product is manufactured by Novo Nordisk, which also makes Wegovy injection and Ozempic.
“Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management.”
Julian Beach, MHRA
The UK is the third country globally to approve the medicine after the US and the UAE. It is the first in Europe.
The clinical evidence in full
The approval is based on the OASIS 4 phase 3 trial in 307 adults with obesity or overweight without type 2 diabetes over 64 weeks.
| Outcome | Oral semaglutide | Placebo |
|---|---|---|
| Mean weight loss, on-treatment | 16.6% | 2.7% |
| Mean weight loss, treatment-policy | 13.6% | 2.4% |
| At least 5% weight loss | 79% | 31% |
| At least 10% weight loss | 63% | 14% |
| At least 15% weight loss | 50% | 6% |
| At least 20% weight loss | About 34% | About 3% |
The 16.6% figure represents participants who remained on treatment. The 13.6% figure includes all randomised participants and is the more conservative measure. Both are clinically meaningful.
Adverse events leading to discontinuation occurred in 6.9% of participants. Serious adverse events were reported in 3.9% on tablet versus 8.8% on placebo. Post-hoc analysis also suggested blood-pressure improvement and normalisation of blood glucose in more than 70% of participants with prediabetes at baseline.
How the pill compares with existing UK weight-loss treatments
| Treatment | Ingredient | Route | Average trial weight loss | Needle-free | UK status |
|---|---|---|---|---|---|
| Mounjaro | Tirzepatide | Weekly injection | About 22.5% | No | Available |
| Wegovy injection | Semaglutide | Weekly injection | About 17.5% | No | Available |
| Wegovy pill | Semaglutide | Daily tablet | About 16.6% on-treatment | Yes | Approved June 2026 |
| Mysimba | Naltrexone and bupropion | Tablet | About 6% to 9% | Yes | Available |
| Orlistat | Orlistat | Tablet or capsule | About 3% to 5% | Yes | Available |
The Wegovy pill opens a new position in the market. It sits far above older tablet treatments on trial efficacy and close to injectable semaglutide, while removing the needle requirement altogether.
The dose schedule and administration rules
| Step | Daily dose | Typical timing |
|---|---|---|
| 1 | 1.5mg | Weeks 1 to 4 |
| 2 | 4mg | Weeks 5 to 8 |
| 3 | 9mg | Weeks 9 to 12 |
| 4 | 25mg | Week 13 onward |
The pill must be taken first thing in the morning, after at least 8 hours of fasting, with no more than 120ml of plain water, and then followed by a 30-minute wait before food, drink other than water, or other medicines. That routine is a major route difference versus injections.
NHS access
The injection already has a NICE pathway. The pill does not. A separate NICE appraisal is needed before NHS prescribing can begin, which means private prescribing is the practical near-term route and 2027 is a more realistic NHS horizon.
What is known about cost so far
UK pricing is still early, but the first confirmed public numbers matter:
- Voy: from £79 per month at starter level on a six-month plan.
- Simple Online Pharmacy: £129 per month, with a £30 new-patient discount.
Maintenance-dose pricing is more important than entry pricing for long-term comparison. We will keep the live route on the Wegovy pill page updated as more providers confirm full-dose pricing.
For broader context, use the cost comparison area, the treatment comparisons hub, and the core all UK treatment routes guide.
The switching protocol for current injection users
The MHRA confirmed that patients currently established on Wegovy 2.4mg weekly injection can transition directly to Wegovy 25mg daily tablet where a prescriber decides that is appropriate. That is a clinically important detail because it means the oral route is not only for new starters.
Why this matters beyond a single product launch
The scale of apparent demand suggests the pill is opening treatment to people who would not have started an injectable GLP-1. Chemist4U has reported more than 10,000 people on its waitlist, and three quarters had reportedly never used a weight-loss injection. Simple Online Healthcare has reported more than 55,000 update registrations.
“The approval of the once-daily oral form of Wegovy is welcome news for people living with obesity, particularly those who would prefer not to use injections.”
Professor Naveed Sattar, University of Glasgow
The pill does not replace Mounjaro, Wegovy injection or the wider provider-comparison market. It adds an important new route for people who want clinically meaningful GLP-1 treatment in tablet form.
What to watch as providers launch
- Clear GPhC registration and prescribing information.
- Published dose schedule rather than vague sales wording.
- Explicit separation between Wegovy pill and Rybelsus.
- Pricing tied to dose and plan length.
- Support and follow-up details.
Start with the Wegovy pill comparison route, then use the supporting provider hub, injection treatment hub and tablet treatment guide. For portfolio-wide oral treatment tracking, the external GLP-1 tablets tracker and tablet comparison site are also relevant follow-on reads.
Frequently asked questions
Is the Wegovy pill now approved in the UK?
Yes. The MHRA approved it on 11 June 2026 for weight management in adults who meet the licensed criteria.
How does it compare with injections?
It delivers slightly lower average weight loss than injectable Wegovy and clearly lower average weight loss than Mounjaro, but it removes the injection barrier entirely.
Will it be available on the NHS this year?
No. A NICE appraisal is still needed, so routine NHS use in 2026 is not expected.
What does it cost?
Early public pricing starts at £79 with Voy and £129 with Simple Online Pharmacy, but long-term maintenance pricing is still emerging.
Where should I start if I want the live route?
Start with the Wegovy pill page and then use the surrounding treatment, provider and cost hubs.
Sources
- MHRA approval announcement, 11 June 2026
- Novo Nordisk press release, 11 June 2026
- NEJM: OASIS 4 oral semaglutide 25mg trial
- Bloomberg reporting on Chemist4U waitlist, 10 June 2026
Last updated: 13 June 2026.
This article is for information only and does not constitute medical advice.
Related articles
Important information
This website is an informational comparison hub. It does not prescribe, supply or sell prescription-only medicines. Suitability depends on a regulated clinical assessment.
Some links may be affiliate or commercial links. Commercial relationships must not change the way safety, eligibility, source checks or editorial context are presented.